Cancer vaccine - Replikun Biotech

Drug Profile

Cancer vaccine - Replikun Biotech

Alternative Names: KUN-GMCSF; KUNrep cancer vaccine - Replikun Biotech

Latest Information Update: 13 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Replikun Biotech
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Oct 2010 Discontinued - Preclinical for Cancer in Australia (Parenteral)
  • 28 Feb 2006 Replikun Biotech has been awarded $Aus1 million grant from AusIndustry to support development of KUN-GMCSF™ over the next 3 years
  • 07 Feb 2006 KUN-GMCSF™ is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top